Related Experiment Video
Updated: Mar 7, 2026

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Diverse repetitive element RNA expression defines epigenetic and immunologic features of colon cancer
Niyati Desai1,2, Dipti Sajed2, Kshitij S Arora1,2,3
1Massachusetts General Hospital Cancer Center.
Abstract:
There is tremendous excitement for the potential of epigenetic therapies in cancer, but the ability to predict and monitor response to these drugs remains elusive. This is in part due to the inability to differentiate the direct cytotoxic and the immunomodulatory effects of these drugs. The DNA-hypomethylating agent 5-azacitidine (AZA) has shown these distinct effects in colon cancer and appears to be linked to the derepression of repeat RNAs. LINE and HERV are two of the largest classes of repeats in the genome, and despite many commonalities, we found that there is heterogeneity in behavior among repeat subtypes. Specifically, the LINE-1 and HERV-H subtypes detected by RNA sequencing and RNA in situ hybridization in colon cancers had distinct expression patterns, which suggested that these repeats are correlated to transcriptional programs marking different biological states. We found that low LINE-1 expression correlates with global DNA hypermethylation, wild-type TP53 status, and responsiveness to AZA. HERV-H repeats were not concordant with LINE-1 expression but were found to be linked with differences in FOXP3+ Treg tumor infiltrates. Together, distinct repeat RNA expression patterns define new molecular classifications of colon cancer and provide biomarkers that better distinguish cytotoxic from immunomodulatory effects by epigenetic drugs.
Insights
Predicting responses to epigenetic therapies like 5-azacitidine (AZA) in colon cancer is challenging. Distinct repeat RNA patterns, specifically LINE-1 and HERV-H, can classify tumors and predict drug response.
Area of Science:
- Genomics
- Cancer Biology
- Epigenetics
Background:
- Epigenetic therapies show promise for cancer treatment, but predicting patient response remains difficult.
- Differentiating direct cytotoxic and immunomodulatory effects of epigenetic drugs is a key challenge.
- 5-azacitidine (AZA), a DNA-hypomethylating agent, exhibits distinct effects in colon cancer, potentially linked to repeat RNA derepression.
Purpose of the Study:
- To investigate the role of repeat RNAs, specifically LINE-1 and HERV-H, in colon cancer.
- To determine if distinct repeat RNA expression patterns can serve as biomarkers for epigenetic drug response.
- To explore the correlation between repeat RNA expression and tumor biological states and immune infiltrates.
Main Methods:
- RNA sequencing and RNA in situ hybridization were used to detect LINE-1 and HERV-H expression in colon cancers.
- Analysis of expression patterns in relation to global DNA methylation, TP53 status, and FOXP3+ Treg infiltrates.
- Correlation of repeat RNA expression with responsiveness to 5-azacitidine (AZA).
Main Results:
- LINE-1 and HERV-H subtypes exhibit distinct expression patterns in colon cancer.
- Low LINE-1 expression correlates with global DNA hypermethylation, wild-type TP53, and AZA responsiveness.
- HERV-H expression is linked to differences in FOXP3+ Treg tumor infiltrates and is not concordant with LINE-1 expression.
Conclusions:
- Distinct repeat RNA expression patterns define novel molecular classifications of colon cancer.
- These patterns can serve as biomarkers to differentiate cytotoxic from immunomodulatory effects of epigenetic drugs.
- Understanding repeat RNA heterogeneity provides insights into predicting and monitoring epigenetic therapy response.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Non-LTR Retrotransposons
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Replicative Cell Senescence
RNA Polymerase II Accessory Proteins

